Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cance…
This Double Take video from the New England Journal of Medicine describes the case of a 35-year-old man presenting with 4 years of shortness of…
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with…
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic …
A 76-year-old retired cardiovascular nurse presented to the ED with 2 hours of chest pain triggered by severe emotional distress and associated with changes in…
Use of some antifungal pesticides may select for resistant fungi in the environment, which can then endanger human health. Coordinated regulatory processes in this area…
Quick Take Video Summary from The New England Journal of Medicine — Nerandomilast for Progressive Pulmonary Fibrosis
Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in…
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic …
Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are…
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic …
